Enrollment for a Phase 1b basket clinical trial of povetacicept (ALPN-303), an experimental anti-inflammatory therapy, for adults with cold agglutinin disease (CAD) and other autoimmune cytopenias is expected to start in the coming months. That’s according to a corporate update from the treatment’s developer, Alpine Immune Sciences. Basket…
Read more
A treatment to reduce the activation of the immune complement system didn’t increase the effectiveness of red blood cell transfusions in people with severe cold agglutinin disease (CAD) and other complement-mediated autoimmune hemolytic anemia (CM-AIHA). That’s according to a small, proof-of-concept Phase 2 clinical trial (EudraCT2012-003710-13) that found…
A Phase 1 trial testing Annexon Biosciences’ oral treatment candidate ANX1502 — for complement-mediated autoimmune disorders such as cold agglutinin disease (CAD) — in healthy volunteers has moved to its multiple-dosing phase. The company is planning to launch a proof-of-concept study of ANX1502 in people with CAD later…
Cold agglutinin disease (CAD) is a rare disorder in which the immune system mistakenly attacks red blood cells, resulting in anemia.
CAD is characterized by autoantibodies, called cold agglutinins, binding to and activating the destruction of red blood cells when exposed to cold temperatures.
Symptoms of CAD include fatigue, Raynaud’s syndrome, joint pain, jaundice or skin discoloration, and heart problems. These symptoms can worsen with more cold exposure.
Get regular updates to your inbox.
